Stonegate Initiates Coverage on Alpha Cognition, Projects Strong Growth for New Alzheimer's Drug
Alpha Cognition's newly approved Alzheimer's drug ZUNVEYL is positioned to address a significant market gap with a potentially safer treatment option, as Stonegate Capital Partners initiates coverage with a valuation range of $27.62 to $38.44 per share.
Following Alpha Cognition Inc.'s (NASDAQ: ACOG) recent FDA approval for its Alzheimer's treatment ZUNVEYL, Stonegate Capital Partners has initiated coverage of the company, highlighting significant market potential for the second oral Alzheimer's therapy approved this decade.
ZUNVEYL addresses a critical need in Alzheimer's treatment, where 55% of patients currently discontinue existing therapies within a year due to severe side effects. The drug's innovative design bypasses GI absorption, potentially reducing common side effects like nausea and vomiting that often lead to treatment discontinuation.
With 7 million Alzheimer's patients in the U.S. and 11 million prescriptions written annually, ZUNVEYL is targeting the long-term care market, which represents a $2 billion opportunity. The company's strategic focus on the LTC sector, where 65-70% of patients have access to zero-dollar copays, could accelerate adoption rates.
Alpha Cognition's commercial preparations include a 33-person sales force covering 80% of LTC providers, with launch planned for Q1 2025. The company has also secured a $44 million licensing deal with China Medical Systems Holdings, indicating potential for global expansion. Market research suggests strong physician interest, with 88% expressing willingness to prescribe ZUNVEYL.
Stonegate's analysis, using a DCF model, values Alpha Cognition between $27.62 and $38.44 per share, with a mid-point of $32.34. The valuation reflects confidence in ZUNVEYL's market potential and the company's strong commercial infrastructure ahead of launch.